Sophiris Bio Inc. (SPHS) Reaches New 52-Week High at $5.61
Sophiris Bio Inc. (NASDAQ:SPHS) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $5.61 and last traded at $5.27, with a volume of 5,052,377 shares. The stock had previously closed at $4.38.
A number of analysts recently commented on SPHS shares. Echelon Wealth Partners reissued a “buy” rating and set a $5.00 price objective on shares of Sophiris Bio in a report on Friday, June 10th. Maxim Group reissued a “buy” rating and set a $4.00 price objective on shares of Sophiris Bio in a report on Friday, June 10th.
The company’s market cap is $117.40 million. The company has a 50 day moving average price of $2.52 and a 200-day moving average price of $1.77.
Sophiris Bio (NASDAQ:SPHS) last posted its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.06. On average, analysts forecast that Sophiris Bio Inc. will post ($0.73) EPS for the current year.
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.